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Background: Previously some groups demonstrated that CD44 variant 6 (CD44v6) is correlated with progression
and metastasis of ovarian cancer. However, a number of other groups failed to find such an association. Moreover,
epithelial ovarian cancer is known to easily metastasize to distinct sites such as the pelvic and abdominal cavities,
but the potential association of CD44v6 expression with site-specific metastasis of ovarian cancer has not been
explored. This study sought to evaluate the expression of CD44 standard (CD44s) and CD44v6 in primary, metastatic
and recurrent epithelial ovarian cancer to explore the potential association of CD44s and CD44v6 with tumor
progression and recurrence.
Methods: Tumor specimens were procured from patients with advanced (FIGO III, G3) and recurrent ovarian serous
adenocarcinoma. CD44s and CD44v6 expression in the tumor tissues was evaluated by real-time RT-PCR and
Western blot. Moreover, serum soluble CD44s or CD44v6 concentrations of early stage (FIGO I, G1), advanced (FIGO
III, G3) and recurrent ovarian serous adenocarcinoma patients were determined by enzyme-linked immunosorbent
assays (ELISA). CD44v6 expression in a different set of tumor samples on an ovarian cancer tissue chip was
evaluated by immunohistochemistry (IHC) and the correlation of CD44v6 expression with clinicopathologic features
was analyzed. Finally, the effects of knockdown of CD44v6 in SKOV3 cells on cell adhesion, invasion and migration
were assessed.
Results: The expression of CD44v6, but not CD44s, is up-regulated in recurrent ovarian serous cancer compared to
advanced primary tumor. CD44v6 expression is also preferentially increased in the tumor at the abdominal cavity
metastasis site of advanced diseases. Consistently, serum soluble CD44v6 levels of recurrent ovarian cancer were
higher than those of early stage and advanced primary diseases. The IHC data demonstrate that CD44v6 expression
is correlated with clinicopathologic features and tumor progression. Lastly, knockdown of CD44v6 decreases the
adhesion and migration but not invasion capacities of SKOV3 cells.
Conclusions: CD44v6 expression levels are associated with epithelial ovarian cancer progression, metastasis and
relapse. Moreover, serum soluble CD44v6 may be used as a potential marker for identifying tumor relapse. Finally,
CD44v6 may play a role in ovarian cancer metastasis by mediating tumor cell adhesion and migration.
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Epithelial ovarian cancer is the most lethal gynecological
cancer and one of the common causes of cancer-related
deaths in women worldwide [1-3]. Epithelial ovarian
cancer is characterized by frequent development of pel-
vic and abdominal cavity metastases in its asymptomatic
stage [2]. As a result, over 75% of ovarian cancer pa-
tients had already developed metastases when they were
first diagnosed. Despite initial chemosensitivity and im-
proved surgical procedures, abdominal recurrence re-
mains a serious clinical issue since it often results in
poor prognosis [4]. Thus, it is critical to identify and de-
velop specific markers and novel therapeutic strategies
for advanced and recurrent ovarian cancer.
CD44 is a transmembrane glycoprotein which functions
primarily as an important cell surface adhesion molecule
interacting with hyaluronan [5]. CD44 is encoded by a sin-
gle gene which contains 20 exons and located on the short
arm of chromosome 11 (11p13) [6]. Alternative splicing of
exons 6–15 (variant exons 1–10) gives rise to numerous
variant forms of CD44 (CD44v), in which an additional
segment encoded by one or more of the variant exons is
inserted in the extracellular domain of CD44s, which is
encoded by exons 1–5 and exons 16–20 [5,7]. CD44s and
CD44v are expressed in a wide variety of cell types includ-
ing epithelial and hematopoietic cells [8,9]. In addition,
the soluble form of CD44s and CD44v also exits [10], and
the soluble proteins have been shown to derive from the
proteolytic cleavage of the membrane-associated CD44s
and CD44v [11].
CD44s and CD44v have been shown to mediate the cell-
extracellular matrix interaction in various biological pro-
cesses such as lymphocyte homing [12], hematopoiesis
[13], embryogenesis [14], and wound-healing [15]. How-
ever, aberrant expression of CD44v has been implicated in
the initiation, progression and recurrence of various hu-
man cancers [16-18]. Also, it has been demonstrated that
CD44s and CD44v have the potential to be used as diag-
nostic and/or prognostic factors for a number of cancers
including bladder cancer [19], colorectal cancer [20],
breast cancer [21], and lung cancer [22].
Among numerous CD44v, CD44v6 was initially shown
to be able to promote the metastatic potential of a rat
pancreatic adenocarcinoma cell line in animal models
[23,24]. Since these seminal studies, it has been
established that CD44v6 plays role in tumor develop-
ment and progression in a variety of human cancers
such as breast cancer [25] and ovarian cancer [26]. Spe-
cifically, CD44v6 has been shown to promote ovarian
cancer metastasis by mediating ovarian tumor cell at-
tachment to the peritoneum [27]. Moreover, numerous
studies have also been carried out to assess the correl-
ation of CD44v6 with tumor development and progres-
sion to address the diagnostic and prognostic values ofCD44v6 for ovarian cancer [28-37]. However, these stud-
ies generated conflicting data.
In the current study, we further investigate the expres-
sion of CD44s and CD44v6 in primary, metastatic and
recurrent epithelial ovarian cancer to explore the poten-
tial association of CD44s and CD44v6 with tumor pro-
gression and recurrence.Methods
Patient samples
Between January 2010 and December 2011, tumor tis-
sues and peripheral blood were obtained from 45 pa-
tients (mean age: 54.17±9.43 years) with advanced
(FIGO III, G3) and 20 patients (mean age: 50.23±6.24years)
with recurrent ovarian serous adenocarcinoma in the De-
partment of Obstetrics and Gynecology, Ren ji Hospital,
School of Medicine, Shanghai Jiao Tong University, Shang-
hai, China. The recurrent tumor tissues were chosen from
tumor nodes of pelvic recurrent site, abdominal metastasis
specimens from omentum, and pelvic metastasis samples
from any pelvic apparatus peritoneum tumor nodes. In
addition, peripheral blood was collected from 10 patients
with early-stage (FIGO I, G1) ovarian serous adenocarcin-
oma as control. The exclusion criteria were inadequate
follow-up data, and chemotherapy/radiotherapy before
operation. The tumor tissues were snap-frozen in liquid
nitrogen and blood samples were frozen at -80°C. This
study was approved by ethics committee of Ren ji Hos-
pital, School of Medicine, Shanghai Jiao Tong University,
and it was in compliance with the Helsinki Declaration.
All the patients gave written informed consent for partici-
pation in the study.Quantitative real-time RT-PCR
Total RNA was extracted from tumor tissues using
Trizol (Invitrogen). The quantity and quality of RNA
were assessed using a NanoDrop 1000 (Thermo). cDNA
was synthesized using the cDNA Reverse Transcription
kit (TAKARA) according to the manufacturer’s instruc-
tions. PCR reactions were performed using the Realtime
PCR system (Applied Biosystems 7500) with the following
conditions: 2 min at 50°C followed by 40 cycles of 95°C,
10 min; 95°C, 15 sec; 60°C, 1 min. Each 10 μl reaction
contained SYBR Premix Ex Taq 5 μl, Primer mix 0.15 μl,
cDNA 1.5 μg, ddH2O 3.85 μl. Primers for CD44s
and CD44v: 50-CCTTTGATGGACCAATTACCATAAC-30
and 50-TCAGGATTCGTTCTGTATTCTCCT-30; Primers
for CD44v6: 50-GGCAACAGATGGCATGAGGG-30 and
50-AGTGGTATGGG-ACCCCCCACTGGGG-30; Primers
for GAPDH: 50-CACATGGCCTCCAAGGAGTAA-30 and
50-TGAGGGTCTCTCTCTTCCTCTTGT-30. The experi-
ment was repeated once with triplicate measurements in
each experiment. Relative CD44s/CD44v6 mRNA levels
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GAPDH mRNA levels.
Western blot
100 μg tumor tissues were lysed using Mem-PER
Eukaryotic Membrane Protein Extraction kit (PIERCE,
Cat No: 89826). Equal amounts of protein were
separated by SDS-PAGE and transferred to PVDF
membrane, which was blocked using 5% BSA in Tris-
Buffered saline with Tween 20. The membrane was
incubated overnight at 4°C with primary antibodies
(Anti-CD44s, Cat Log#: ab119863, Abcam; anti-CD44v6,
Cat Log#: MAB4073, Millpore; 1:5000). After incubation,
the membrane was rinsed and incubated for 1 hour at
room temperature in appropriate anti-mouse HRP-
conjugated secondary antibody (1:10,000). The mem-
brane was rinsed, developed and specific protein bands
were detected with the infrared fluorescence scanning
imaging system (odyssey Li-Cor). GAPDH served as
loading control. Relative CD44s/CD44v6 expression
levels are calculated as ratios of CD44s/CD44v6 band
density to that of GAPDH.
Enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assay kits (CD44s, Cat
Log#: KA0119; CD44v6, Cat Log#: KA0120, Abnova) for
quantitatively detecting soluble CD44s or CD44v6 levels
in patient sera were used according to the manufac-
turer’s instructions. Briefly, the sera were added in dupli-
cate to the wells of the microtiter plate coated with an
antibody against CD44s or CD44v6 with horseradish
peroxidase-conjugate. Then, absorbance at the wave
length of 450 nm in each microwell was measured using
a spectrophotometer.
Immunohistochemistry
Ovarian Cancer Tissue Chip (Cat No: BC11115) was
purchased from Xi’an Alena Biotechnology Ltd. The tis-
sue chip contains 80 samples of epithelial ovarian cancer,
10 samples of metastasis lymph nodes and 10 samples of
edge tissues of normal ovary. IHC staining of the tissue
chip was performed using EliVision plus IHC Kit
(Maixin Biological Ltd, Fuzhou, China) following the
manufacturer’s instructions. The tissue chips were
roasted at 60°C for 30 min for deparaffinization and then
were placed in 10 mmol/L citrate buffer (pH 6.0) under
the high pressure for 2 min. Endogenous peroxidase ac-
tivity was quenched by 3% hydrogen peroxide in abso-
lute methanol at room temperature for 10 min. Then
they were incubated with primary antibodies (Cat Log#:
Anti-CD44v6, 1:500) overnight at 4°C. The reaction
products were visualized with diaminobenzidine (DAB
Kit, Maixin Biological, Fuzhou, China), and sections
were counterstained with hematoxylin, dehydrated, andevaluated under light microscope. Tris-buffered saline
solution was used as negative controls. The sections were
all quantified by two pathologists in a blinded manner.
The average number of stained cells in 5 visual fields was
regarded as the percent ratio of positively stained cells in
each section. Positive range score: 0, 0–5%; 1, 6–25%; 2,
26–50%; 3, 51–75%; 4, >75%. Positive extent score: 0, no
staining; 1, light yellow; 2, brown; 3, dark brown. Judged
by positive range score plus positive extent score: <2,
negative (–); 2–3, slight positive (+); 4–5, moderately posi-
tive (++); 6–7, strongly positive (+++).
For statistics, all the samples that expressed CD44v6
form (+) to (+++) were regards as positive.
Cell culture
SKOV3 cells, a human serous ovarian cancer cell line
from ATCC, were cultured in RPMI1640 medium sup-
plemented with 10% fetal bovine serum (HyClone),
100 U/mL penicillin and streptomycin, in a 5% CO2
atmosphere at 37°C.
Small interfering RNA (siRNA) knockdown of CD44v6
SKOV3 cells were transiently transfected with siRNA
obtained from Shanghai Integrated Biotech Solutions
Co., Ltd. siRNA-1 against CD44v6: sense 50-UGAGGG
AUAUCGCC-AAACATT-30 and anti-sense 50-UGUUU
GGCGAUAUCCCUCATT-30; siRNA-2 against CD44v6:
sense 50-GCAACUCCU-AGUAGUACAAT-T-30 and anti-
sense50-UUGUACUA-CUAGGAGUUGCTT-30; and siRNA-
NC: sense 50-UUCUCCGAACGUGUCACGUTT-30 and
anti-sense50-ACGUGACACGUUCGGA-GAATT-30) using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. Following transfection, cells were
incubated at 37°C in a CO2 incubator for 24 or 48 hours
before being harvested for quantitative real time RT-PCR
and Western blot analyses.
Cell-extracellular matrix (ECM) adhesion assay
96-well plates were pre-coated with 50 uL Matrigel
(diluted 1:8) for 4 hours at 37°C. Matrigel became solidi-
fied and simulated the major components of ECM. The
cells (5×104) were seeded (in triplicate for each condi-
tion) in coated wells with 100 uL of serum-free RPMI
1640, and allowed to adhere for 60 min at 37°C and 5%
CO2. Then the non-adherent cells were washed with
PBS. Adherent cells were counted with the Cell
Counting Kit 8 (Dojindo, Tokoy, Japan) according to the
manufacturer’s protocol. The adhesion rates were then
calculated.
Cells invasion and migration assays
Transwell filters (Millipore) were coated with Matrigel
(diluted 1:5) on the upper surface of the polycarbonic
membrane (diameter of 12 mm, pore size 8 mm). After
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(transfected for 48 h) and control cells (4×105)
suspended in 200 uL of serum-free RPMI 1640 were
added to the upper chamber and 500 uL contained 20%
FBS RPMI 1640 were added to the low chamber. After
16 hours of incubation at 37°C in a 5% CO2 incubator,
the cells that had invaded the lower surface of the filter
were fixed with 4% paraformaldehyde and stained with
crystal violet. The invaded cells were counted by light
microscopy and the average numbers of cells of at least
five fields from each well were calculated. In a similar
fashion, the cells migration were evaluated using the
same transwell filters without coated with the Matrigel,
and other conditions and the analysis were the same as
the invasion assay. Triplicate assays were performed for
each group of cells in both the invasion and migration.
Statistical analysis
Statistical analysis was performed using SPSS version
13.0. Quantitative real time RT-PCR, Western blot, ad-
hesion assay, migration assay, and invasion assay data
were analyzed using Student’s t-test and expressed as
mean ± SD. The correlation between CD44v6 positive
expression and the clinicopathologic parameters was
assessed by Chi-square test. Differences were consideredFigure 1 Expression of CD44 and CD44v6 in advanced primary and re
concentrations of soluble CD44s (sCD44s) and CD44v6 (sCD44v6) in p
ovarian cancer. (A) Real-time RT-PCR analysis of mRNA levels of CD44 (usi
CD44v) and CD44v6 (using a pair of primers specific to CD44v6) in 45 adva
**: P<0.01. (B) Western blot analysis of CD44s and CD44v6 protein levels in
A. *: P<0.05. (C) Representative images of Western blots performed in B. (D
from patients with early-stage, advanced-stage and recurrent epithelial ova
ELISA was repeated three times. **: P<0.01.statistically significant when P values are smaller than
0.05.
Results
CD44v6 expression is up-regulated in recurrent human
ovarian serous tumors compared to primary tumors
First we determined the levels of CD44 (a mixed popula-
tion of CD44s and CD44v) and CD44v6 transcripts in
samples from primary and recurrent tumors of ovarian
serous cancer using real-time RT-PCR. Our data reveal
that while there is no significant difference in CD44
mRNA levels between primary and recurrent tumors,
CD44v6 mRNA levels in the recurrent disease are sig-
nificantly higher than those in the primary adenocarcin-
oma (Figure 1A). This finding was further supported by
Western blot analysis demonstrating that primary and
recurrent tumors express similar levels of CD44s pro-
teins but the recurrent disease expresses significantly
higher levels of CD44v6 protein than the primary tumor
(Figure 1B-C). These data indicate that the expression of
CD44v6, but not CD44s, is up-regulated in recurrent
ovarian serous tumors compared to primary tumors.
To further investigate the association of CD44v6
with progression and recurrence of ovarian serous
adenocarcinoma, we measured serum soluble CD44scurrent epithelial ovarian cancer tissues, and serum
atients with early-stage, advanced-stage and recurrent epithelial
ng a pair of primers complementary to common regions of CD44s and
nced primary tumor samples and 20 tissues from recurrent diseases.
the same set of advanced primary and recurrent tumor samples as in
) Serum levels of sCD44s and sCD44v6 in peripheral blood samples
rian cancer were determined by ELISA as described in Methods. The
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recurrent ovarian serous adenocarcinoma patients by
ELISA. The results demonstrate that soluble CD44s
levels among early-stage, advanced-stage and recurrent
diseases had the trend of gradual decreases without sig-
nificant differences among the three groups. However,
serum soluble CD44v6 levels of the recurrent disease
were markedly increased compared to those of early-
stage and advanced diseases (Figure 1D). This finding
suggests that the serum soluble CD44v6 concentration
may be used as a potential marker for recurrent ovarian
serous tumors.
CD44v6 expression is increased in tumor tissues from the
abdominal cavity metastasis compared to those from the
primary and pelvic metastasis sites
Next, we sought to examine and compare CD44s and
CD44v6 expression in tumors at the primary site versus
the pelvic and abdominal cavity metastasis sites of the
same patients. To this end, we selected 28 out of the 45
cases of the advanced ovarian serous adenocarcinoma
since we had obtained tumor specimens from the pri-
mary site (primary site), the abdominal cavity metastasis
site (Met-1), and the pelvic cavity metastasis site (Met-2)
for each of these 28 advanced diseases. As in the previ-
ous study (Figure 1), we carried out both real-time RT-Figure 2 Expression of CD44 and CD44v6 in tumor samples from diff
of mRNA levels of CD44 (using a pair of primers complementary to commo
specific to CD44v6) in tumor tissues from the primary site, the abdominal c
patients with advanced ovarian cancer. **: P<0.01. (B) Western blot analysis
samples as in A. *: P<0.05. (C) Representative images of Western blots perfoPCR and Western blot analysis to assess the expression
of CD44s and CD44v6 in tumor samples from the differ-
ent tumor sites. Our data show that whereas tumors at
the primary and two metastasis sites exhibit similar
levels of CD44s expression both at the mRNA level
(Figure 2A) and at the protein level (Figure 2B-C), tu-
mors at the abdominal cavity metastasis site expresses
significantly higher levels of CD44v6 both at the mRNA
level (Figure 2A) and at the protein level (Figure 2B-C)
than those at the primary site or the pelvic cavity metas-
tasis site. Thus, these findings indicate that CD44v6 ex-
pression is preferentially increased in tumors at the
abdominal cavity metastasis site of the advanced ovarian
serous adenocarcinoma.
CD44v6 expression is correlated with clinicopathologic
features and tumor progression
To further investigate the association of CD44v6 expres-
sion with progression and metastasis of ovarian cancer,
we examined CD44v6 expression in tumor tissues on an
ovarian cancer tissue chip by IHC. This tissue chip con-
tains 80 samples of epithelial ovarian cancer, 10 samples
of metastasis lymph nodes and 10 samples of edge tis-
sues of normal ovary. We categorized these samples
according to four different clinicopathologic parameters:
age (<50 years or ≥50 years), histological typeserent locations in the same patients. (A) Real-time RT-PCR analysis
n regions of CD44s and CD44v) and CD44v6 (using a pair of primers
avity metastasis (Met-1) and the pelvic cavity metastasis (Met-2) of 28
of CD44s and CD44v6 protein levels in the same set of tumor
rmed in B.
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tiation grade (G1, G2, G3) (Table 1). Representative IHC
staining images of grade 3 ovarian serous adenocarcin-
oma, lymph node metastasis, edge tissues of normal
ovary and corresponding negative controls are shown in
Figure 3 to demonstrate the efficient detection of
CD44v6 expression in the tumor samples on the tissue
chip.
The IHC data show that while there is no difference in
the percentage of CD44v6 positive tumor cells between
the two age groups and two pathological type groups,
significant differences in the percentage of CD44v6 posi-
tive tumor cells exist in other clinicopathologic parame-
ters. The positive CD44v6 expression rates of FIGO
stage II and III tumors were 83.33% and 85.00%, respect-
ively, which both are higher than that of FIGO I tumor
(44.12%), (p<0.05, Table 1). Moreover, the positive
CD44v6 expression rates of G2 and G3 tumors were
88.46% and 85.29%, respectively, which both are signifi-
cantly higher than that of G3 tumors (35.29%), (p<0.05,
Table 1). This indicates that the poorer the tumor differ-
entiation, the higher the CD44v6 expression. These data
reveal that CD44v6 expression is correlated with the
clinicopathologic features and tumor progression.
Knockdown of CD44v6 decreases the adhesion and
migration but not invasion capacities of SKOV3 cells
The data obtained from the analysis of the clinical sam-
ples above suggest that CD44v6 may play a role in medi-
ating tumor metastasis. To explore this possibility, we
extended our study to knock down CD44v6 expressionTable 1 Correlation of the clinicopathologic features and
CD44v6 expression positive rate
CD44v6 expression
Clinicopathologic parameters n — + ++ +++ Positive rate
Age
<50y 45 20 12 9 4 55.56
≥50y 45 16 11 14 4 64.44
Pathological type
Mucinous 10 5 4 0 1 50.00
Serous 59 16 20 17 6 72.88
FIGO stage
I 34 19 9 4 2 44.12
II 12 2 2 7 1 83.33
III 20 3 11 4 2 85.00
Differentiation grade
G1 17 11 3 2 1 35.29
G2 26 3 12 7 4 88.46
G3 34 5 15 11 3 85.29
Correlation of CD44v6 expression positive rate with the
clinicopathologic features.in SKOV3 cells, a human serous ovarian cancer cell line,
and assess the impact of knockdown of CD44v6 on the
adhesion, invasion and migration capacities of SKOV3
cells. Transient transfection of SKOV3 cells with two
distinct siRNAs (siRNA-1 and siRNA-2) led to a signifi-
cant reduction in CD44v6 mRNA levels (Figure 4A) and
protein levels (Figure 4B and 4C). Then, we used paren-
tal SKOV3 cells and SKOV3 cells transfected with
control siRNA (siRNA-NC), siRNA-1 or siRNA-2 to per-
form cell adhesion, migration and invasion assays as de-
scribed in Methods. The data indicate that SKOV3 cells
with CD44v6 knockdown showed a decreased cell adhe-
sion (Figure 5A) and migration (Figure 5C) compared
with the cells transfected with siRNA-NC control
groups. However, we found that knockdown of CD44v6
in SKOV3 cells did not affect the invasion capacity of
this human serous ovarian cancer cell line (Figure 5B).
Taken together, these findings suggest that CD44v6 may
play a role in ovarian cancer metastasis by mediating
tumor cell adhesion and migration.
Discussion
Recently, numerous studies have focused on investigat-
ing the expression of CD44v6 in malignancy to address
the association of CD44v6 with tumor progression, me-
tastasis and recurrence. So far, CD44v6 has been shown
to be a useful prognostic factor for a variety of cancers
including those of the stomach [38], head and neck [39],
prostate [40], and lung [22]. As expected, a number of
groups have also investigated the expression of CD44v6
in ovarian cancer to examine the potential correlation of
this CD44 variant with ovarian cancer development and
progression. However, the data from these studies are
not consistent. While several studies demonstrated that
soluble CD44v6 is not associated with the development
and metastasis of ovarian cancer [28,30,33], other inves-
tigations showed that CD44v6 is correlated with tumor
progression and metastasis [32,35-37]. These studies are
further in conflict with one study showing that CD44v6,
together with CD44s and CD44v3, are inversely associ-
ated with the ovarian carcinoma FIGO stage [31]. Fur-
thermore, several questions regarding the correlation of
CD44v6 with ovarian cancer metastasis remain to be an-
swered. For example, epithelial ovarian cancer is known
to metastasize to distinct sites such as the pelvic and
abdominal cavities; it is still not clear whether CD44v6
expression is associated with site-specific metastasis of
ovarian cancer.
In light of the controversy and unanswered questions,
we carried out independent studies to further address
the association of CD44v6 with development and pro-
gression of ovarian cancer. Most previous studies
assessed CD44v6 expression using one or two methods
[28,30,32,33,35-37]. To obtain accurate and reliable data,
Figure 3 IHC analysis of CD44v6 expression in tumor tissues on an Ovarian Cancer Tissue Chip. Representative IHC staining images of
grade 3 ovarian serous adenocarcinoma (A) and corresponding negative control (D), grade 2 lymph node metastatic serous adenocarcinoma
(B) and corresponding negative control (E), and edge tissues of normal ovary (C) and corresponding negative control (F).
Figure 4 Efficient knockdown of CD44v6 in SKOV3 cells by transfected siRNA against CD44v6. (A) Quantitative real-time RT-PCR analysis of
mRNA levels of CD44v6 expression in parental SKOV3 cells and SKOV3 cells transiently transfected with control RNA, siRNA-NC, siRNA-1 and
siRNA-2. **: P<0.01. (B) Western blot analysis of CD44v6 protein levels in the same set of SKOV3 cell as in A. *: P<0.05. (C) Representative images
of Western blots performed in B.
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Figure 5 Assessment of the adhesion, invasion and migration capacities of SKOV3 cells with CD44v6 knockdown. (A) Cell adhesion
assays with parental SKOV3 cells and SKOV3 cells transiently transfected with siRNA-NC, siRNA-1 and siRNA-2. (B) Cell invasion assays with parental
SKOV3 cells (a) and SKOV3 cells transiently transfected with siRNA-NC (b), siRNA-1 (c) and siRNA-2 (d). (C) Cell migration assays with parental
SKOV3 cells (a) and SKOV3 cells transiently transfected with siRNA-NC (b), siRNA-1 (c) and siRNA-2 (d).
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tumor specimens collectively by three methods: quanti-
tative real-time RT-PCR, Western blot analysis and IHC
analysis. Our first study aimed to examine CD44v6 ex-
pression in tumor tissues from patients with advanced
(FIGO III, G3) and recurrent ovarian serous adenocar-
cinoma. Our data indicate that CD44v6 expression is
associated with ovarian serous cancer recurrence
(Figure 1), which is consistent with the finding of a pre-
vious study in which CD44v6 expression was assessed by
IHC [29]. We then extended our study to investigate
CD44v6 expression in tumor samples from the primary
site and two different metastasis sites. Interestingly, we
found that CD44v6 expression is correlated with the ab-
dominal cavity metastasis of epithelial ovarian cancer
(Figure 2). Furthermore, CD44v6 expression in a differ-
ent set of tumor samples on an ovarian cancer tissue
chip was evaluated by immunohistochemistry (IHC)
(Figure 3). The IHC data demonstrated that CD44v6 ex-
pression is correlated with clinicopathologic features and
tumor progression (Table 1).
More importantly, we found that serum soluble
CD44v6 levels are significantly higher in patients with
recurrent diseases than in those with advanced primary
diseases (Figure 1D). Soluble CD44 and CD44v are de-
rived from the proteolytic cleavage of the membrane-
associated CD44 and CD44v [11]. Soluble CD44 and
CD44v can be detected in human sera and other body
fluids and thus they have the potential to be used as
diagnostic factor for tumor burden and metastasis [41].
Elevated serum concentrations of soluble CD44s and
CD44v6 have been shown to correlate with tumor pro-
gression and metastasis of gastric carcinoma, colon car-
cinoma or breast cancer [41-43]. Our current study has
revealed that soluble CD44v6 levels are correlated with
ovarian cancer recurrence, indicating that serum soluble
CD44v6 also has the potential to be used as a diagnostic
marker for monitoring ovarian tumor recurrence.
Liottta et al initially proposed the theory of tumor me-
tastasis process, which consists of three steps: adhesion,
degradation and metastasis [44]. These investigators
demonstrated that the adhesion was the first and the
most important step of tumor metastasis. In ovarian
cancer alterations in the extracellular environment are
critical for tumor initiation and progression and intra-
peritoneal dissemination. Extracellular matrix molecules
including versican and hyaluronan which interacts with
CD44 have been shown to play key roles in ovarian can-
cer metastasis [26]. Our results indicate that CD44v6 ex-
pression is only up-regulated in tumor tissues from the
recurrent disease and abdominal cavity metastasis site,
suggesting that CD44v6 may be an adhesion molecule
during the process of ovarian cancer cell adhesion and
metastasis. Moreover, SKOV3 cell adhesion and migra-tion were decreased after knocking down CD44v6 ex-
pression by siRNA, indicating that CD44v6 may play a
role in mediating tumor cell adhesion and migration
during the metastasis process. Therefore, we propose
that CD44v6 may also have the potential to serve as an
effective therapeutic target for preventing and treating
the recurrence and abdominal cavity metastasis of ovar-
ian cancer.
Conclusions
In conclusions, our current work demonstrates that
CD44v6 expression levels are associated with progres-
sion, metastasis and relapse of epithelial ovarian cancer.
Furthermore, serum soluble CD44v6 may be used as a
potential marker for identifying tumor relapse. Finally,
CD44v6 may play a role in ovarian cancer metastasis by
mediating tumor cell adhesion and migration. Signifi-
cantly, these studies have not only provided more con-
vincing evidence supporting the correlation of CD44v6
expression levels with ovarian cancer progression, me-
tastasis and relapse but have also laid a foundation for
future investigations to further explore the potential of
CD44v6 as a diagnostic marker for monitoring ovarian
tumor recurrence and as an effective therapeutic target
for preventing and treating the recurrence and abdom-
inal cavity metastasis of ovarian cancer.
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